RU2740913C2 - Лечение нарушений со стороны печени, желчных путей и поджелудочной железы - Google Patents

Лечение нарушений со стороны печени, желчных путей и поджелудочной железы Download PDF

Info

Publication number
RU2740913C2
RU2740913C2 RU2018141326A RU2018141326A RU2740913C2 RU 2740913 C2 RU2740913 C2 RU 2740913C2 RU 2018141326 A RU2018141326 A RU 2018141326A RU 2018141326 A RU2018141326 A RU 2018141326A RU 2740913 C2 RU2740913 C2 RU 2740913C2
Authority
RU
Russia
Prior art keywords
defensin
seq
hbd
fat
liver
Prior art date
Application number
RU2018141326A
Other languages
English (en)
Russian (ru)
Other versions
RU2018141326A (ru
RU2018141326A3 (enExample
Inventor
Питер НОРДКИЛД
Сёрен КЬЕРУЛЬФ
Original Assignee
Дефенсин Терапьютикс Апс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дефенсин Терапьютикс Апс filed Critical Дефенсин Терапьютикс Апс
Publication of RU2018141326A publication Critical patent/RU2018141326A/ru
Publication of RU2018141326A3 publication Critical patent/RU2018141326A3/ru
Application granted granted Critical
Publication of RU2740913C2 publication Critical patent/RU2740913C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2018141326A 2016-04-29 2017-04-28 Лечение нарушений со стороны печени, желчных путей и поджелудочной железы RU2740913C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201670276 2016-04-29
DKPA201670276 2016-04-29
DKPA201670484 2016-07-01
DKPA201670484 2016-07-01
PCT/DK2017/050132 WO2017186250A1 (en) 2016-04-29 2017-04-28 Treatment of liver, biliary tract and pancreatic disorders

Publications (3)

Publication Number Publication Date
RU2018141326A RU2018141326A (ru) 2020-05-29
RU2018141326A3 RU2018141326A3 (enExample) 2020-08-06
RU2740913C2 true RU2740913C2 (ru) 2021-01-21

Family

ID=58992579

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018141326A RU2740913C2 (ru) 2016-04-29 2017-04-28 Лечение нарушений со стороны печени, желчных путей и поджелудочной железы

Country Status (11)

Country Link
US (1) US12076368B2 (enExample)
EP (1) EP3448409B1 (enExample)
JP (1) JP2019514908A (enExample)
KR (1) KR102465341B1 (enExample)
CN (1) CN109414474B (enExample)
AU (1) AU2017258242B2 (enExample)
BR (1) BR112018071972A2 (enExample)
CA (1) CA3022497A1 (enExample)
RU (1) RU2740913C2 (enExample)
SG (1) SG11201809086YA (enExample)
WO (1) WO2017186250A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
JP7479381B2 (ja) * 2019-01-07 2024-05-08 アエスクルス バイオ エーピーエス 治療または予防に使用するためのディフェンシン断片
CN110279851A (zh) * 2019-07-05 2019-09-27 浙江大学 Defa4细胞因子在制备治疗肝功能衰竭药剂中的应用
CN114058694A (zh) * 2021-11-29 2022-02-18 上海市普陀区中心医院 Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用
KR102735773B1 (ko) * 2022-11-10 2024-11-27 을지대학교 산학협력단 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148078A1 (en) * 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
CN104971343A (zh) * 2015-07-13 2015-10-14 韩源平 防御素在制备治疗代谢综合征药物方面的应用
CN105504063A (zh) * 2015-10-19 2016-04-20 中国医学科学院医药生物技术研究所 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
WO2003101394A2 (en) 2002-05-31 2003-12-11 Ciphergen Biosystems, Inc. Defensins: use as antiviral agents
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
WO2007133373A2 (en) 2006-05-01 2007-11-22 England Robert L TNF-α VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-α
WO2008115390A2 (en) * 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
WO2010007166A2 (en) 2008-07-18 2010-01-21 Novozymes A/S Treatment of inflammatory bowel diseases with mammal beta defensins
NZ590466A (en) 2008-07-18 2012-08-31 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins
SG2014012918A (en) 2009-02-11 2014-04-28 Novozymes Biopharma Dk As Albumin variants and conjugates
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
US20110311601A1 (en) 2010-06-22 2011-12-22 Michael Kleine Antimicrobial medical devices
DE102010040153A1 (de) 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
SG11201500682WA (en) 2012-09-07 2015-02-27 Sanofi Sa Fusion proteins for treating a metabolic syndrome
KR20180121489A (ko) 2016-01-26 2018-11-07 디펜신 테라퓨틱스 에이피에스 장내 미생물을 조절하는 방법
CN108026130B (zh) * 2016-07-30 2021-04-02 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
CN114075585A (zh) * 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种β-烟酰胺单核苷酸的制备方法
CN112795606B (zh) * 2021-04-14 2021-07-27 深圳瑞德林生物技术有限公司 一种β-烟酰胺单核苷酸的酶催化合成方法
CN114107160B (zh) * 2021-12-27 2025-04-25 浙江英沃迪生物科技有限公司 一种烟酰胺核糖激酶基因工程菌及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148078A1 (en) * 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
CN104971343A (zh) * 2015-07-13 2015-10-14 韩源平 防御素在制备治疗代谢综合征药物方面的应用
CN105504063A (zh) * 2015-10-19 2016-04-20 中国医学科学院医药生物技术研究所 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BELIKOV V.G. Pharmaceutical Chemistry: M., Higher School, 1993, p. 43-47. *
Mattar E.H. et.al. Virucidal activity of human α- and β-defensins against hepatitis C virus genotype 4 // Molecular BioSystems, V. 12, N. 9, 01.01.2016, P. 2785 - 2797. *
Mattar E.H. et.al. Virucidal activity of human α- and β-defensins against hepatitis C virus genotype 4 // Molecular BioSystems, V. 12, N. 9, 01.01.2016, P. 2785 - 2797. БЕЛИКОВ В.Г. Фармацевтическая химия: М., Высшая школа, 1993, с. 43-47. *

Also Published As

Publication number Publication date
AU2017258242B2 (en) 2024-04-04
KR102465341B1 (ko) 2022-11-09
AU2017258242A1 (en) 2018-11-29
RU2018141326A (ru) 2020-05-29
RU2018141326A3 (enExample) 2020-08-06
EP3448409A1 (en) 2019-03-06
WO2017186250A1 (en) 2017-11-02
CA3022497A1 (en) 2017-11-02
CN109414474B (zh) 2024-07-02
US20190192626A1 (en) 2019-06-27
US12076368B2 (en) 2024-09-03
EP3448409B1 (en) 2025-12-03
SG11201809086YA (en) 2018-11-29
CN109414474A (zh) 2019-03-01
KR20190003592A (ko) 2019-01-09
JP2019514908A (ja) 2019-06-06
BR112018071972A2 (pt) 2019-02-26

Similar Documents

Publication Publication Date Title
JP6890135B2 (ja) 腸内微生物叢を調節するための方法
RU2740913C2 (ru) Лечение нарушений со стороны печени, желчных путей и поджелудочной железы
RU2635966C2 (ru) Фармацевтическая композиция для предупреждения или лечения неалкогольной жировой болезни печени
CA2887272C (en) Exendin-4 derivatives as dual glp1/glucagon agonists
CN107129538B (zh) Glp-1受体激动剂和胃泌素的肽缀合物及其用途
JP2021138740A (ja) Ｇｉｐアゴニスト化合物及び方法
JP2023071869A (ja) グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
Jiang et al. Oral administration of soybean peptide Vglycin normalizes fasting glucose and restores impaired pancreatic function in Type 2 diabetic Wistar rats
US11773150B2 (en) Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
ES3023833T3 (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
BRPI0610091B1 (pt) Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico
JP2016540741A (ja) Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2020059735A (ja) 神経性状態および神経変性状態の治療としての長時間作用型ＧＬＰ−１ｒアゴニスト
HK40001163B (en) Methods for modulating intestinal microbiota
RU2779314C2 (ru) Коагонисты рецепторов глюкагона и glp-1 длительного действия
HK1184466A (en) Peptide conjugates of glp-1 receptor agonists and gastrin and their use